focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Share News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Abcam Buys Applied StemCell Gene Editing Platform, Oncology Portfolio

Thu, 30th Jan 2020 10:51

(Alliance News) - Abcam PLC on Thursday said it has purchased Applied StemCell Inc's gene editing platform and oncology product portfolio for an undisclosed sum.

Life sciences company Abcam said the deal "includes a portfolio of cell lines and the well-regarded AccuRef reference materials product line". StemCell's proprietary platform is used to create cell lines which have uses in "a broad range of diseases", including drug discovery.

Most cells have a finite number of divisions. However, in a cell line, cells will keep growing and dividing indefinitely, which makes them easier to study.

Abcam did not disclose financial terms of the deal, although it said the acquisition is "expected to have a minimal impact on revenue and earnings in the current financial year", which ends in June.

Cheri Walker, senior vice president of Corporate Development at Abcam, said: "This transaction expands and cements Abcam's position in the edited cell line market, bringing in one of the most widely deployed and technically successful cell engineering platforms into Abcam. The cell line market is in the early stages of development as a research tool, where the ready provision of more choice, with the right gene targets in the right cell lines, will allow the market to rapidly expand."

Shares in Abcam were down 0.1% at 1,405.00 pence in London in morning trading.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
25 Jul 2016 15:15

Abcam describes 'another successful year' ahead of results

(ShareCast News) - Life science research tools supplier Abcam posted a trading update for the year to 30 June on Monday, ahead of the publication of its financial results, due 12 September. The AIM-traded firm described "another successful year" and claimed to have achieved above market revenue grow

Read more
20 Jun 2016 15:35

Abcam announces Wood as new finance chief

(ShareCast News) - Life science research tools firm Abcam announced on Monday the appointment of Gavin Wood as its chief financial officer. The AIM-traded firm said Wood, who is the former executive vice president and CFO of Affymetrix, is to join the company on 18 July and succeed Jeff Iliffe after

Read more
20 Jun 2016 06:40

Abcam Appoints Gavin Wood As New Chief Financial Officer

Read more
5 Apr 2016 08:32

BROKER RATINGS SUMMARY: Liberum Upgrades Babcock To Hold From Sell

Read more
14 Mar 2016 09:33

BROKER RATINGS SUMMARY: HSBC And Merrill Lynch Downgrade Admiral

Read more
10 Mar 2016 16:13

Dividends Calendar - Week Ahead

Read more
7 Mar 2016 14:30

Abcam shares sink on news of lower earnings

(ShareCast News) - Abcam tried to paint its interim results as strong on Monday, with the biotechnology company making increased investment for the future, though the market did not agree in afternoon trading. The AIM-traded firm saw revenue rise 17.2% on a constant currency basis and 18% on a repor

Read more
7 Mar 2016 07:51

Abcam Confident In Meeting Full-Year Targets As COO To Retire

Read more
29 Feb 2016 16:08

Earnings, Trading Statements Calendar - Week Ahead

Read more
26 Jan 2016 09:43

BROKER RATINGS SUMMARY: UBS Upgrades RBS To Buy From Neutral

Read more
25 Jan 2016 10:36

Avacta Poaches Abcam's Cotrel For Chief Commercial Officer Role

Read more
25 Jan 2016 07:56

Abcam Expects Revenue Growth Of 17% For First Half

Read more
5 Jan 2016 09:43

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

Read more
27 Nov 2015 15:44

Dividends Calendar - Week Ahead

Read more
11 Nov 2015 16:40

DIRECTOR DEALINGS: Abcam CEO Buys GBP19,343 Of Stock After AxioMx Deal

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.